Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
Condition or disease
Relapsed or Refractory Chronic Lymphoproliferative Disorders
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients with relapsed or refractory chronic lymphoproliferative disorders treated with bendamustine +/- rituximab
patients with relapsed or refractory chronic lymphoproliferative disorders